Short answer
BridgeBio Pharma, Inc. (BBIO) filed an 8-K current report with the SEC on July 2, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 7.01 (Regulation FD Disclosure), Item EX-99.1 (Exhibit EX-99.1). Press release furnished as Exhibit 99.1 under Item 1.01.
BridgeBio Pharma, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- Press release furnished as Exhibit 99.1 under Item 1.01
- Material agreement details require review of Exhibit 99.1
Item 7.01 · Regulation FD Disclosure
- Item 7.01 contains only standard Regulation FD and incorporation-by-reference disclaimer language
- No substantive investor information or market-moving disclosure appears in the provided text
Item EX-99.1 · Exhibit EX-99.1
- $1B preferred-equity financing strengthens liquidity for launches and pipeline investment
- Sixth Street funded $800M; HealthCare Royalty funded $133.9M at closing
- 7.00% cumulative dividend, payable in cash or kind, creating material funding cost
- Initial conversion price $137.79, more than 100% above 30-day VWAP; increases to $153.10 after year five
- Capital supports potential launches of BBP-418, encaleret, and infigratinib within 12 months
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other BridgeBio Pharma, Inc. 8-K filings
Get the next BBIO 8-K as it lands
Follow BBIO for push alerts, or ask the research agent what this filing means.